Plain-English translation of NCT06291155 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 2 Diabetes research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
Researchers want to understand how canagliflozin, a diabetes medication, works to protect kidneys in people with type 2 diabetes and early kidney damage. This trial will give you the medication for six months while researchers examine changes in your kidney cells using advanced genetic testing and imaging. The goal is to learn exactly how this treatment helps slow kidney disease.
Doctors know this medication can help protect kidneys in diabetic patients, but they don't fully understand the mechanism — the actual cellular changes that make it work. Understanding these details could lead to better treatments and more personalized care for people with diabetes and kidney disease.
You likely qualify if…
You likely don't qualify if…
You would take the medication daily for six months alongside your regular diabetes care. You'll have kidney biopsies (needle samples of kidney tissue) at the start and after six months, with kidney imaging performed near each biopsy. You'll also have blood and urine tests, kidney function measurements, and special MRI imaging of your kidneys. After the six-month treatment period ends, you'll be followed up annually for additional safety monitoring.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States